IL2 and metastatic malignant neoplasm: These efforts resulted in 1985 in the first safe administration of LAK cells together with IL-2 to patients with metastatic cancer.10 In subsequent trials, however, the benefit of LAK cells proved small in comparison to IL-2 administration11,12 making research in more antigen-specific cytotoxic immune cells necessary.